Antibiotics save lives, but they are not fail-safe. Even when microbes haven't acquired drug-evading genetic mutations—a hallmark of antibiotic resistance—the medications don't always clear infections.
Blame it on the dry and wet climate of India that provides a perfect breeding grown for the bacteria, thus increasing the risk of bacterial infections. This coupled with the easy availability of OTC antibiotics to quickly tackle the infection without a doctor's prescription, there is growing abuse of antibiotics, and hence, antibiotic resistance.
Expressing concern over the growing resistance against antibiotics in the country, the Indian Medical Association (IMA) has come out with a draft policy on use of antibiotics in human healthcare aiming at reining in antimicrobial resistance (AMR).
No newer antibiotic molecules have been are invented in last 30 years. The antibiotics that are currently available are only modifications of the existing molecules have been tried out. This is one of the reasons for antibiotic resistance and the multidrug-resistant microorganisms are a real threat to healthcare in India.
Total number of antibiotic tablets/capsules to be taken for the prescribed duration shall be mentioned in the prescription and not just the dose administration schedule. Appropriate antibiotics should be prescribed at the earliest to manage suspected sepsis, meningitis, pneumonia or positive cases of tuberculosis.
Every medical establishment can draw its own antibiotic policy (IV to oral antibiotic switch, antibiotic preference based on local antibiogram, infection prevention and control, reuse of medical devices and safe syringe practices). MDR TB and XDR TB are required to be notified to health authorities and surveillance teams (IDSP). Doctors need to ensure root cause analysis for any outbreak of MDR infection in hospital/healthcare facility. All food products must be labeled with "Antibiotic status". Antibiotic waste disposal policy to be developed to prevent contamination of the environment; preventing discharge of untreated waste into soil and rivers, it added.
The antibiotics R&D pipeline is dry, with very little new research being done on antibiotics. Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions.